uniQure initiated with an Outperform at Baird. Baird analyst Madhu Kumar initiated uniQure with an Outperform rating and a price target of $85. The analyst cites his conviction that its Factor IX adeno-associated virus gene therapy AMT-061 “has the potential to disrupt the treatment of hemophilia B, with enrollment completion into the Phase 3 HOPE-B trial setting the stage for upside” fore uniQure shares.
https://thefly.com/landingPageNews.php?id=2885881
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.